The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.
AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete
Gilead Sciences' Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a reg
Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.